Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: a VBM study; the Parkinson's Disease Cognitive Impairment Study (PaCoS)
Giulia Donzuso1, Roberto Monastero2, Calogero E Cicero1
1Department of Surgical and Medical Sciences Advanced Technologies "G.F. Ingrassia", University of Catania, Via Santa Sofia 78, Catania, 95123, Italy.
Introduction:
Mild cognitive impairment (MCI) is common in Parkinson's disease (PD), but the underlying pathological mechanism has not been fully understood. Voxel-based morphometry could be used to evaluate regional atrophy and its relationship with cognitive performances in early PD-MCI.
Patients And Methods:
One hundred and six patients with PD were recruited from a larger cohort of patients, the Parkinson's Disease Cognitive Impairment Study (PaCoS). Subject underwent a T1-3D MRI and a complete clinical and neuropsychological evaluation. Patients were divided into PD with normal cognition (PD-NC) and PD-MCI according to the MDS level II criteria-modified for PD-MCI. A subgroup of early patients with short disease duration (≤ 2 years) was also identified. VBM analysis between PD-NC and PD-MCI and between early PD-NC and PD-MCI was performed using two-sample t tests with whole-brain statistical threshold of p < 0.001 uncorrected in the entire PD group and p < 0.05 FWE inside ROIs, in the early PD.
Results:
Forty patients were diagnosed with MCI and 66 were PD-NC. PD-MCI patients showed significant gray matter (GM) reduction in several brain regions, including frontal gyrus, precuneus, angular gyrus, temporal lobe, and cerebellum. Early PD-MCI showed reduction in GM density in superior frontal gyrus and cerebellum. Moreover, correlation analysis between neuropsychological performances and GM volume of early PD-MCI patients showed associations between performances of Raven and superior frontal gyrus volume, Stroop time and inferior frontal gyrus volume, accuracy of Barrage and volume of precuneus.
Conclusion:
The detection of frontal and cerebellar atrophy, even at an early stage, could be used as an early marker of PD-related cognitive impairment.
Insights
Brain atrophy in the frontal and cerebellar regions is linked to mild cognitive impairment in Parkinson's disease (PD). Early detection of this gray matter reduction may serve as a key biomarker for cognitive decline in PD patients.
Area of Science:
- Neuroimaging
- Neurology
- Cognitive Science
Background:
- Mild cognitive impairment (MCI) is prevalent in Parkinson's disease (PD), but its pathological basis remains unclear.
- Voxel-based morphometry (VBM) can assess regional brain atrophy and its correlation with cognitive function in early PD-MCI.
Purpose of the Study:
- To investigate regional brain atrophy patterns in Parkinson's disease patients with mild cognitive impairment (PD-MCI).
- To explore the relationship between gray matter volume and cognitive performance in early PD-MCI.
Main Methods:
- 106 Parkinson's disease patients were recruited and underwent MRI and neuropsychological evaluations.
- Patients were classified into PD with normal cognition (PD-NC) and PD-MCI groups, including an early PD subgroup (disease duration ≤ 2 years).
- Voxel-based morphometry (VBM) was used to compare gray matter density between groups.
Main Results:
- PD-MCI patients exhibited significant gray matter reduction in the frontal gyrus, precuneus, angular gyrus, temporal lobe, and cerebellum.
- Early PD-MCI showed gray matter density reductions in the superior frontal gyrus and cerebellum.
- Cognitive performance in Raven's tests, Stroop, and Barrage correlated with gray matter volumes in the frontal lobe and precuneus.
Conclusions:
- Frontal and cerebellar atrophy are detectable even in early stages of Parkinson's disease.
- These atrophic changes can serve as early indicators of cognitive impairment in PD.
Related Concept Videos
Parkinson's Disease: Overview
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Alzheimer's Disease: Treatment


